Organon & Co. (NYSE:OGN) Stock Position Raised by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lifted its stake in Organon & Co. (NYSE:OGN - Free Report) by 191.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 760,807 shares of the company's stock after acquiring an additional 499,616 shares during the period. Allspring Global Investments Holdings LLC owned 0.30% of Organon & Co. worth $11,382,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Sippican Capital Advisors lifted its position in Organon & Co. by 4.3% in the third quarter. Sippican Capital Advisors now owns 15,230 shares of the company's stock worth $291,000 after purchasing an additional 627 shares during the period. Commerce Bank lifted its holdings in shares of Organon & Co. by 5.5% in the third quarter. Commerce Bank now owns 12,168 shares of the company's stock valued at $233,000 after buying an additional 637 shares during the period. MassMutual Private Wealth & Trust FSB boosted its stake in Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock valued at $41,000 after buying an additional 672 shares in the last quarter. Graypoint LLC grew its holdings in Organon & Co. by 6.2% during the third quarter. Graypoint LLC now owns 14,555 shares of the company's stock worth $278,000 after acquiring an additional 853 shares during the period. Finally, Wilmington Savings Fund Society FSB grew its holdings in Organon & Co. by 12.9% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 10,910 shares of the company's stock worth $163,000 after acquiring an additional 1,248 shares during the period. 77.43% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on OGN shares. Barclays reduced their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Morgan Stanley decreased their price target on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Friday, February 14th. Finally, TD Cowen raised Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $20.80.

Organon & Co. Trading Down 1.4 %

Shares of OGN stock traded down $0.23 during trading hours on Friday, reaching $15.47. 3,552,714 shares of the stock traded hands, compared to its average volume of 2,857,395. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The firm has a market capitalization of $3.98 billion, a PE ratio of 4.64, a PEG ratio of 0.85 and a beta of 0.76. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10. The business has a fifty day moving average price of $15.36 and a 200 day moving average price of $17.28.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. On average, equities research analysts forecast that Organon & Co. will post 3.78 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 13th. Shareholders of record on Monday, February 24th will be given a dividend of $0.28 per share. The ex-dividend date is Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.24%. Organon & Co.'s payout ratio is presently 33.63%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.